Merck's cholesterol drug clears main goal in late-stage study
June 27 Merck & Co Inc said on Tuesday its cholesterol drug met its main goal of reducing coronary heart diseases in a late-stage study.
March 10 Crossroads Systems Inc
* Crossroads systems reports fiscal first quarter 2017 financial results
* Q1 loss per share $0.36 Source text for Eikon: Further company coverage:
* FactSet reports solid earnings growth in third quarter 2017
* Chesapeake energy says Director Brad Martin reports open market purchase of 20,400 shares of co's common stock at $4.55/share on june 23 - SEC filing Source text for Eikon: (http://bit.ly/2shU2g8) Further company coverage: